Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Veldona · 1 trial · 3 indications
A patient with a 75% or greater decrease in total OU for three visits was considered a "sustained responder".
| Arm | Type | Description |
|---|---|---|
| 1 | PLACEBO_COMPARATOR | (placebo)0 IU IFNa |
| 2 | EXPERIMENTAL | (Veldona)500 IU IFNα bid |
| 3 | EXPERIMENTAL | (Veldona)1000 IU IFNα bid |
| Name | Type | Description |
|---|---|---|
| Veldona, | BIOLOGICAL | Very low dose oral natural human interferon alpha lozenges |
Inclusion Criteria: * Is a male or a non-pregnant, non-lactating female. * Has a history and clinical presentation consistent with a diagnosis of Behçet's Disease and meets International Study Group criteria (Appendix B). * Has a history of oral ulcers for at least 12 months. * Has a history of mon...
Veldona is an investigational monoclonal antibody being studied for the treatment of Behcet Syndrome, specifically for oral ulcers associated with the condition. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
Veldona is being developed by Ainos, Inc., a biopharmaceutical company. The company's stock is traded under the ticker symbol AIMD.
Veldona is in Phase 2 clinical development. It is an investigational drug and has not yet received regulatory approval. A Phase 2 clinical trial for Veldona in Behcet Syndrome has been completed.
Veldona has one completed Phase 2 clinical trial registered under NCT00483184, titled 'Low Dose Interferon Alpha Treatment for Oral Ulcers of Behcet's Disease.' The trial enrolled 84 participants with Behcet Syndrome and mucocutaneous ulceration in Turkey.
Veldona is a monoclonal antibody, not interferon alpha. The completed clinical trial NCT00483184 evaluated low-dose interferon alpha treatment for oral ulcers in Behcet's disease, but Veldona itself is a distinct investigational monoclonal antibody.